Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
ClinicalTrials.gov Studies
Summary
This is a single-center, single-arm, Phase 2 trial (NCT07550920) evaluating retlirafusp alfa combined with single-agent chemotherapy as neoadjuvant treatment for patients with resectable Stage II-III EGFR/ALK wild-type non-small cell lung cancer (NSCLC). Eligible patients receive 4 cycles of neoadjuvant therapy, followed by curative surgery and 1 year of maintenance therapy with retlirafusp alfa. Primary endpoints are pathological complete response (pCR) rate and safety.
“This is a single-center, single-arm, phase 2 trial evaluating the efficacy and safety of retlirafusp alfa combined with single-agent chemotherapy as neoadjuvant treatment for patients with resectable stage II-III EGFR/ALK wild-type non-small cell lung cancer (NSCLC).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document is a clinical trial registry entry for a Phase 2 single-center study investigating retlirafusp alfa combined with single-agent chemotherapy as neoadjuvant treatment for resectable Stage II-III EGFR/ALK wild-type NSCLC. The trial involves 4 cycles of neoadjuvant therapy followed by curative surgery and 1 year of maintenance therapy. Primary endpoints are pathological complete response rate and safety.
Healthcare providers and clinical investigators should note this registry entry as it may represent a referral opportunity or collaborative research pathway for patients with resectable Stage II-III NSCLC.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
Phase 2 NCT07550920 Kind: PHASE2 Apr 24, 2026
Abstract
This is a single-center, single-arm, phase 2 trial evaluating the efficacy and safety of retlirafusp alfa combined with single-agent chemotherapy as neoadjuvant treatment for patients with resectable stage II-III EGFR/ALK wild-type non-small cell lung cancer (NSCLC).Eligible patients receive 4 cycles of neoadjuvant therapy, followed by curative surgery and 1-year maintenance therapy with retlirafusp alfa.Primary endpoints are pathological complete response (pCR) rate and safety. Secondary endpoints include major pathological response (MPR), event-free survival (EFS), and overall survival (OS).
Conditions: NSCLC
Interventions: Drug: Retlirafusp alfa, Drug: Single-agent Chemotherapy, Procedure: Radical Surgery
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.